Table 5.
Colostrum dosage forms used for treating internal pathologies and external wounds.
| Types of Injuries | Colostrum dosage form | Number of patients enrolled in clinical trials (Male/Female) | Endpoints monitored | Effect observed | Dose and study duration | Reference |
|---|---|---|---|---|---|---|
| Gastrointestinal injury due to non-steroidal anti-inflammatory drugs | Colostrum powder in the form of tablets/capsules. | 7 (7/0) |
Intestinal permeability | IGF and TGF-β responsible for analgesic activity | 125 ml t.i.d. for 7 days | (Playford et al., 2001) |
| Inflammation induced for HIV patients for infection in gastroesophageal tract. | Colostrum powder in the form of tablets/capsules or liquid colostrum. | 87 (27/60) | Stool frequency; self-reported fatigue; CD4+ count; body weight |
Mucosal integrity, tissue repair, and antimicrobial actions | 16 G b.i.d. for 4 weeks | (Kaducu et al., 2011) |
| Diabetes Delayed injury healing due to increase in blood glucose levels | Colostrum topical cream or colostrum powder in the form of tablets/capsules. | 18 (9/9) |
Postprandial blood glucose; triglycerides; cholesterol; ketone bodies |
Reduction of blood glucose, which starts wound healing problem in diabetic patients. | 10 G daily | (Kim et al., 2009) |
| Repair of muscle, bone tissue, skin cartilage, and nerve cells. | Colostrum topical cream or colostrum powder in the form of tablets/capsules | No clinical studies were done in humans; only in vitro cell line studies were done. | Increases the migration of WI38 fibroblasts | Nucleotides, epidermal growth factor, transforming growth factor, and IGF-1 promote wound healing and DNA, RNA damage repair. | 10 G per 100 G of cream composition | (Takayama et al., 2001) |
| Ultraviolet B (UVB)-induced photo damage | Colostrum topical cream | Pre-clinical studies done on seven-week-old male Hos : HR-1 hairless mice. | Trans-epidermal water loss starts to increase. | Lactoferrin capable of preventing damage to the skin | 10 G per 100 G of the cream composition | (Murata et al., 2014) |
| Infection with diarrhoeic E. coli in children |
Colostrum powder in the form of tablets/capsules | 27 (13/14) | Stool frequency; elimination of strainsexpressing virulence factors | Decrease stool frequency | 21 G once daily for 14 days | (Huppertz et al., 1999) |
| Chronic pain syndrome | Colostrum powder in the form of tablets/capsules | 4(2/2) | Flow cytometry; cytokine analysis;IGF-1; apoptosis | Apoptotic effect on monocytes | 20 G once daily for 14 days | (Waaga-Gasser et al., 2009) |
| Inflammatory bowel disease (IBD) | Colostrum enemas | 14(6/8) | Mild-to-moderate severe distal colitis (IBD), histological score was used for clinical assessment | Improvement in histological scores showed reduction of IBD symptoms. | 100 ml of 10% BC solution enemas b.i.d | (Khan et al., 2002) |